New and emerging AD treatments a Plenary highlight

Dr. Simpson: “It’s always nice to have options because of the heterogeneity of the disease.”

Atopic dermatitis (AD) has become one of the most commonly presented skin conditions in the United States. In Friday’s Plenary session, Eric L. Simpson, MD, MCR, discussed the latest AD trends in his presentation “New Developments in Atopic Dermatitis — From Barrier to Burden to Biologics.”

Dr. Simpson included an update on AD treatment options. Historically, the only FDA-approved systemic therapy was prednisone. Within the last two years, the FDA has approved two alternatives: crisaborole (Eucrisa) and dupilumab (Dupixent.) Both medicines have pros (not steroids) and cons (high price and potential of intolerable side effects), with dupilumab seeing a higher success rate for chronic AD.

While the development of new therapies is exciting for the future of AD, there is much more progress ahead. New research is being dedicated to understanding the significance of dupilumab’s IL-4 inhibition. Researchers inadvertently began picking it out while examining IL-13 inhibitors lebrikizumab and tralokinumab.

“It’s always nice to have options because of the heterogeneity of the disease and because there will be patients who don’t respond to dupilumab or get adequate response,” said Dr. Simpson recently in a Dermatology World article.

This is just a starting point for AD. There are many other ongoing studies and trials being done to analyze the effects of biologic and JAK inhibitors. Dr. Simpson also discussed innovative prophylactic strategies and novel approaches to patient assessment.

At the conclusion of his Plenary presentation, Dr. Simpson said: “We’re about a year away from finding out whose drug is the best to treat atopic dermatitis and what the side effect profile looks like. It’s super exciting.”

Dr. Simpson is professor of dermatology at Oregon Health and Science University School of Medicine with special interest in chronic inflammatory skin diseases. He is actively involved in clinical and translational research and is currently funded by the National Institutes of Health and industry partners to study new approaches to treatment and prevention.

Dr. Simpson supports patient advocacy by serving as the co-chair of the Scientific Advisory Committee for the National Eczema Association. He also serves on the executive committee of the Harmonizing Outcome Measures in Eczema (HOME), a volunteer group of patients, providers, and other stakeholders whose mission is to improve the quality of eczema research to better suit the needs of patients and policymakers.

To learn more about atopic dermatitis, read the full Dermatology World cover story “Filling the medicine cabinet” from the August 2018 issue.

 

Return to index

Top